- Lobbying
- Lobbying by Global Blood Therapeutics
Lobbying Relationship
Bills mentioned
H.R.2113: Prescription Drug STAR Act
Sponsor: Richard E. Neal (D-Mass.)
S.2543: Prescription Drug Pricing Reduction Act of 2019
Sponsor: Charles E. Grassley (R-Iowa)
H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
Sponsor: Frank Pallone (D-N.J.)
H.R.19: Lower Costs, More Cures Act of 2019
Sponsor: Greg Walden (R-Ore.)
H.R.6216: Sickle Cell Disease Comprehensive Care Act
Sponsor: Danny K. Davis (D-Ill.)
S.4866: Sickle Cell Disease Treatment Centers Act of 2022
Sponsor: Chris Van Hollen (D-Md.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Darren Willcox | Asst. for Policy, Speaker Dennis Hastert; Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss; House Rules Comm. Assoc., Subcommittee Staff Director |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate